Raises €35.5 Million Through A Capital Increase With European And US Investors
Launches a capital increase to raise approximately €30 Million
Major progress achieved in clinical development and strong cash position
announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients
Financial Information and Business Update
To present in vivo data with odiparcil at the 14th WORLDSymposium™
Lanifibranor: Phase IIb trial in NASH, recruiting now
Lanifibranor: Phase IIb trial in Systemic Sclerosis.
Odiparcil: Phase IIa in MPSVI, recruiting now
No front page content has been created yet.